Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.475 USD | +0.08% | -3.86% | -37.15% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.15% | 186M | |
+7.25% | 217B | |
+13.96% | 195B | |
+30.91% | 112B | |
+3.42% | 65.83B | |
+13.96% | 52.67B | |
+2.72% | 49.86B | |
-5.83% | 38.18B | |
-0.73% | 35.39B | |
+22.22% | 31.02B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target